Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer
To determine the dose and schedule of sirolimus when given in combination with panitumumab in adult subjects with Stage IIIB/IV NSCLC
Oncology|Non-Small Cell Lung Cancer
DRUG: AMG 954/Panitumumab
safety within the first 3 weeks
pharmacodynamic analysis of mTOR
To determine the dose and schedule of sirolimus when given in combination with panitumumab in adult subjects with Stage IIIB/IV NSCLC